Aberrant innate immune profile associated with COVID-19 mortality in Pretoria, South Africa

dc.contributor.authorVan der Mescht, Mieke Adri
dc.contributor.authorDe Beer, Zelda
dc.contributor.authorSteel, Helen Carolyn
dc.contributor.authorAnderson, Ronald
dc.contributor.authorMasenge, Andries
dc.contributor.authorMoore, Penny L.
dc.contributor.authorBastard, Paul
dc.contributor.authorCasanova, Jean-Laurent
dc.contributor.authorAbdullah, Fareed
dc.contributor.authorUeckermann, Veronica
dc.contributor.authorRossouw, Theresa M.
dc.contributor.emailtheresa.rossouw@up.ac.zaen_US
dc.date.accessioned2024-08-28T07:52:25Z
dc.date.available2024-08-28T07:52:25Z
dc.date.issued2024-09
dc.descriptionDATA AVAILABILITY : The datasets analyzed for this study can be made available on request.en_US
dc.description.abstractThe African continent reported the least number of COVID-19 cases and deaths of all the continents, although the exact reasons for this are still unclear. In addition, little is known about the immunological profiles associated with COVID-19 mortality in Africa. The present study compared clinical and immunological parameters, as well as treatment outcomes in patients admitted with COVID-19 in Pretoria, South Africa, to determine if these parameters correlated with mortality in this population. The in-hospital mortality rate for the cohort was 15.79%. The mortality rate in people living with HIV (PLWH) was 10.81% and 17.16% in people without HIV (p = 0.395). No differences in age (p = 0.099), gender (p = 0.127) or comorbidities were found between deceased patients and those who survived. All four of the PLWH who died had a CD4+ T-cell count <200 cells/mm3, a significantly higher HIV viral load than those who survived (p = 0.009), and none were receiving antiretroviral therapy. Seven of 174 (4%) patients had evidence of auto-antibodies neutralizing Type 1 interferons (IFNs). Two of the them died, and their presence was significantly associated with mortality (p = 0.042). In the adjusted model, the only clinical parameters associated with mortality were: higher fraction of inspired oxygen (FiO2) (OR: 3.308, p = 0.011) indicating a greater need for oxygen, high creatinine (OR: 4.424, p = 0.001) and lower platelet counts (OR: 0.203, p = 0.009), possibly secondary to immunothrombosis. Overall, expression of the co-receptor CD86 (p = 0.021) on monocytes and percentages of CD8+ effector memory 2 T-cells (OR: 0.45, p = 0.027) was lower in deceased patients. Decreased CD86 expression impairs the development and survival of effector memory T-cells. Deceased patients had higher concentrations of RANTES (p = 0.003), eotaxin (p = 0.003) and interleukin (IL)-8 (p < 0.001), all involved in the activation and recruitment of innate immune cells. They also had lower concentrations of transforming growth factor (TGF)-β1 (p = 0.40), indicating an impaired anti-inflammatory response. The immunological profile associated with COVID-19 mortality in South Africa points to the role of aberrate innate immune responses.en_US
dc.description.departmentImmunologyen_US
dc.description.departmentInternal Medicineen_US
dc.description.departmentSchool of Health Systems and Public Health (SHSPH)en_US
dc.description.departmentStatisticsen_US
dc.description.librarianhj2024en_US
dc.description.sdgSDG-03:Good heatlh and well-beingen_US
dc.description.sponsorshipThe South African Medical Research Council Self-Initiated Research Grant (SAMRC SIR) funded the project. The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) and R21AI160576), the National Center for Advancing Translational Sciences (NCATS), the NIH Clinical and Translational Science Award (CTSA) program, the Fisher Center for Alzheimer's Research Foundation, the Meyer Foundation, the JPB Foundation, the Stavros Niarchos Foundation (SNF) as part of its grant to the SNF Institute for Global Infectious Disease Research at the Rockefeller University, the “Investissement d'Avenir” program launched by the French Government and implemented by the Agence Nationale de la Recherche (ANR), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence, the French Foundation for Medical Research (FRM), the European Union's Horizon 2020 research and innovation program, the Square Foundation, Grandir - Fonds de solidarité pour l'enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, Battersea & Bowery Advisory Group, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM, Paris Cité University, Imagine Institute and William E. Ford, General Atlantic's Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic's Co-President, Managing Director and Head of Business in EMEA, and the General Atlantic Foundation. A.-L.N. was supported by the Imagine Institute international PhD program (with the support of the Fondation Bettencourt-Schueller) and the FRM, the French Foundation for Medical Research, the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller), and a “Poste CCA-INSERM-Bettencourt” (with the support of the Fondation Bettencourt-Schueller).en_US
dc.description.urihttps://www.elsevier.com/locate/yclimen_US
dc.identifier.citationVan der Mescht, M.A., D Beer, Z., Steel, H.C. et al. 2024, 'Aberrant innate immune profile associated with COVID-19 mortality in Pretoria, South Africa', Clinical Immunology, vol. 266, art. 110323, pp. 1-11, doi : 10.1016/j.clim.2024.110323.en_US
dc.identifier.issn1521-6616
dc.identifier.other10.1016/j.clim.2024.110323
dc.identifier.urihttp://hdl.handle.net/2263/97902
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rights© 2024 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC license.en_US
dc.subjectCOVID-19 pandemicen_US
dc.subjectCoronavirus disease 2019 (COVID-19)en_US
dc.subjectMortalityen_US
dc.subjectPeople living with HIV (PLHIV)en_US
dc.subjectCD86en_US
dc.subjectCytokinesen_US
dc.subjectType 1 IFN antibodiesen_US
dc.subjectType 1 interferons (IFNs)en_US
dc.subjectSDG-03: Good health and well-beingen_US
dc.titleAberrant innate immune profile associated with COVID-19 mortality in Pretoria, South Africaen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
VanDerMescht_Aberrant_2024.pdf
Size:
956.95 KB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
VanDerMescht_AberrantSuppl_2024.pdf
Size:
473.73 KB
Format:
Adobe Portable Document Format
Description:
Supplementary Material

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: